Share Name Share Symbol Market Type
Sanofi EU:SAN Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 94.89 93.61 94.50 0.00 06:15:07

Sanofi's Phase 3 Study of Rilzabrutinib Didn't Meet Primary, Secondary Endpoints

09/09/2021 6:45am

Dow Jones News

Sanofi (EU:SAN)
Historical Stock Chart

From Jul 2021 to Jan 2022

Click Here for more Sanofi Charts.
   By Mauro Orru 

Sanofi SA said Thursday that a Phase 3 study assessing rilzabrutinib for the treatment of pemphigus--a group of potentially life-threatening disorders characterized by blisters and ulceration affecting the skin and mucous membranes--didn't meet its primary or key secondary endpoints.

The French pharmaceutical major said the primary endpoint was complete remission from weeks 29 to 37 with minimal doses of corticosteroids, with results showing that the proportion of patients meeting the primary endpoint wasn't much different from placebo.

However, Sanofi said rilzabrutinib's safety profile was still consistent with previous results and that no new safety signals were identified.

"While these results are disappointing, we believe the rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases," said Naimish Patel, head of global development for immunology and inflammation.

"We are committed to investigating rilzabrutinib further and progressing our clinical programs forward to deliver new treatment options for patients," Mr. Patel said.


Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94


(END) Dow Jones Newswires

September 09, 2021 01:30 ET (05:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Sanofi Chart

1 Year Sanofi Chart

1 Month Sanofi Chart

1 Month Sanofi Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220128 07:26:06